EQL Pharma get Glycopyrronium EQL Pharma approved

EQL Pharma has today received the approval of Glycopyrronium EQL Pharma solution for injection 0.2mg/ml from the Danish Medicines Agency and approvals in Sweden, Norway and Finland are expected shortly.

Glycopyrronium EQL Pharma contains glycopyrronium bromide and is a so-called anticholinergic which is used in hospital care, among other things, to counteract salivary secretion during operations in the mouth, throat or trachea.
 

Glycopyrronium EQL Pharma will be EQL's third approved inpatient care product and will be sold through public tenderering in all four Nordic countries. The market is growing and worth approximately SEK 30 million annually with three active competitors. The launch is dependent on the result of tenders for procurements but can take place at the earliest in the fourth quarter (January-March) of EQL's financial year.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.